skip to main content

SHP-77

SHP-77

Catalogue No.

98110201

Cell Line Name

SHP-77

Cell Line Description

SHP-77 was established in 1977 being derived from a non-encapsulated primary lung tumor from the apical portion of the upper lobe of the left lung. The patient was a 54 year old male with blood type O, Rh+. The cell line has a variety of unusual characteristics including the morphology of an undifferentiated large cell variant of small cell lung carcinoma (SCLC) but biochemical properties of a classical SCLC. SHP-77 express neural cell adhesion molecule (NCAM), NHK-1, CD56 and the cell surface leucocyte antigen Leu-7(HNK-1;CD57). Other neuroendocrine markers are L-dopa decarboxylase and dense core secretory granules. Gland formation and intracytoplasmic lamellar bodies have been shown by electron microscopy. This cell line is useful as in vitro target in 51Cr and III In release cytotoxicity assays. They are suitable for in vitro nude mice assays for evaluation of immune reactivity of cells and serum from lung cancer patients. In addition, they serve to evaluate the immune status of patients with SCLC who received radiation or chemotherapy treatment. SHP-77 cells are tumorigenic in nude mice and grow as circumscribed nodules without metastases formation. They have a reported doubling time of 96 hours.

Characteristics

Tissue of Origin

Lung

DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 10,11
D5S818: 12
D7S820: 11
D13S317: 8
D16S539: 11
TH01: 7
TPOX: 9,11
vWA: 16

Karyotype

Not specified

Applications

SCLC studies, cytotoxicity assays, immunological studies

Disease

Cancer

Culture Conditions

Cell Type

Carcinoma

Subculture Routine

Maintain cultures between 4-9 x 100,000 cells / ml; 5% CO₂; 37°C. Cells grow as mixture of loosely adherent and floating clusters.

Culture Medium

RPMI 1640 + 2mM Glutamine + 10% Heat Inactivated Foetal Bovine Serum (HI-FBS).

Growth Mode

Adherent/aggregates in suspension

Additional Info

Depositor

Obtained from ATCC

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Cancer Res 1978;38:3830, Cancer Res 1985;45:2725, Cancer Res 1991;51:6142, Am J Clin Pathol 1978;69:165, J Exp Clin Res 1985;4:355, Lung Cancer 1988;4:52, Anticancer Res 1993;13:1953

Bibliography

Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, Pineda M, Gindin Y, Jiang Y, Reinhold WC, Holbeck SL, Simon RM, Doroshow JH, Pommier Y, Meltzer PS.2013 The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res. 73(14):4372-82. PMID: 23856246.

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: SHP-77 (ECACC 98110201).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.